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Abstract
Purpose: To evaluate the efficacy and safety of the glycoside fraction of fenugreek (Trigonella foenum-graecum) seeds (Fenu-FG) on physiologi-
cal parameters related to muscle anabolism, androgenic hormones, and body fat in healthy male subjects during an 8-week resistance training
program using a prospective, randomized, double-blind, placebo controlled design.
Methods: Sixty healthy male subjects were randomized to ingest capsules of Fenu-FG (1 capsule of 300 mg, twice per day) or the matching
placebo at a 1:1 ratio. The subjects participated in a supervised 4-day per week resistance-training program for 8 weeks. The outcome
measurements were recorded at recruitment (baseline) and at the end of the treatment (8 weeks). The efficacy outcome included serum testosterone
(total and free) levels, muscle strength and repetitions to failure, metabolic markers for anabolic activity (serum creatinine and blood urea
nitrogen), and % body fat. The standard safety measurements such as adverse events monitoring, vital signs, hematology, biochemistry, and
urinalysis were performed.
Results: Fenu-FG supplementation demonstrated significant anabolic and androgenic activity as compared with the placebo. Fenu-FG treated
subjects showed significant improvements in body fat without a reduction in muscle strength or repetitions to failure. The Fenu-FG supplemen-
tation was found to be safe and well-tolerated.
Conclusion: Fenu-FG supplementation showed beneficial effects in male subjects during resistance training without any clinical side effects.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shanghai University of Sport. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Athletes use many nutritional supplements to improve their
performance regardless of nutritional status.1 Therefore, inter-
est in safer nutritional therapies and supplements for muscle
building and performance enhancement is rising.
All performance enhancing supplements are regulated by the
World Anti-Doping Code as defined by the World Anti-Doping
Agency.2–5 Many traditional herbal medicines are being inves-
tigated as safer alternatives for their nutritional benefits and
performance enhancement. However, they need to be scientifi-
cally evaluated for their efficacy and safety in the relevant
populations using standardized procedures such as randomized
double-blind placebo controlled studies.6,7
Fenugreek, Trigonella foenum-groecum L. (Fabaceae) seeds
extract is a component of many nutritional dietary products that
are recommended for athletes and exercising male subjects.
Fenugreek seeds, a spice and food grain, has traditional history
of medicinal use in the management of type 2 diabetes mellitus
in Egypt, Southern Europe, India, Asia, and North Africa.8
Fenugreek seeds extract is certified as a GRAS (generally rec-
ognized as safe) item under clause §182.20 (essential oils, oleo-
resins and natural extractives including distillates) by the US
Food and Drug Administration.
Traditionally, fenugreek seeds have been reported to be
useful in hormonal regulation, in particular for male impotence
and as a galactagogue in lactating mothers.9 In India, ground
fenugreek seeds mixed with jaggery are recommended for
females after childbirth for their anabolic effects to develop and
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strengthen muscles.10 Recent studies on fenugreek seeds
extracts support their effectiveness in promoting lean body
mass, and lowering cholesterol.11 Fenugreek extract is reported
to enhance endurance capacity and the utilization of fatty acids
as an energy source in male mice.12 One recent study on fenu-
greek extract reported fat reducing effects greater than placebo
in young, healthy resistance-exercising males.13 These effects
are purported to be mediated through an aromatase and 5α
reductase inhibition, thereby increasing total testosterone levels
by blocking its conversion to estrogen and dihydrotestosterone,
respectively.13 Increased testosterone levels are known to
increase muscle size and strength in men14 with downstream
benefits on body weight, body fat, muscle size, strength, libido,
energy, and mood.15,16 Increased total testosterone levels could
potentially affect serum free/bioavailable testosterone concen-
trations, resulting in escalated delivery and use by muscle cells
to enhance protein synthesis, thus positively influencing
strength and body fat. However, direct evidence for the andro-
genic effects of fenugreek seeds extract or its components in
clinical practice is lacking.
Fenugreek seeds are rich in steroidal compounds like glyco-
sides and saponins including diosgenin, yamogenin, gitogenin,
tigogenin, and neotigogens. Diosgenin is an important precur-
sor for the synthesis of a number of sex hormones.17 Diosgenin,
a steroidal sapogenin, is reported to augment overall weight and
muscle growth in rats.18 Moreover, diosgenin is reported
to improve glucose metabolism by promoting adipocyte
differentiation and inhibiting inflammation in adipose
tissues.19 We have previously shown the efficacy of the glyco-
side fraction of fenugreek seeds (Fenu-FG) on testosterone
levels in immature castrated male rats.20 Recently, the excellent
safety profile of sub-chronic (90-day) administration of
Fenu-FG without any effects on body weight has been demon-
strated in rats.21
Taking clues from both traditional and modern literature
regarding the androgenic potential and safety of fenugreek gly-
cosides, the present pilot study investigated furostanol
glycosides-based fenugreek seeds extract (Fenu-FG) supple-
mentation using a prospective, randomized, double blind,
placebo-controlled design in healthy male subjects during an
8-week resistance training programme.
2. Materials and methods
2.1. Study design and protocol
This study was designed as a prospective, double-blind, ran-
domized, placebo controlled study in male subjects and con-
ducted using good clinical practice and ethical guidelines of
Helsinki Declaration. The study protocol was assessed and
approved by the Independent Institutional Human Ethics Com-
mittee. Inclusion criteria were the male healthy volunteers aged
between 18 and 35 years, with normal health status based on
clinical and laboratory examination, willing to sign the written
informed consent form, and trained for resistance exercise at
least for 1 month. The exclusion criteria were the subjects with
any one of the following: (1) Subjects with elevated resting
heart rate (>100 beats per min) or blood pressure (BP) (systolic
BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg); (2) Subjects with
history of medical or surgical events that may affect the study
outcome or place the subject at risk, including cardiovascular
disease, gastrointestinal problems, metabolic, renal, hepatic,
neurological or active musculoskeletal disorders; (3) Subjects
with history of orthopaedic injury or surgery within the last
year; (4) Subjects with known hypersensitivity to herbal
drugs/nutritional supplement/foods; (5) Subjects who were
consuming/have received any performance enhancing therapy
during last 2 months; (6) Subjects undergoing any weight loss
or diet plan during the trial period; (7) Chronic alcoholics; (8)
Drug abusers; (9) Subjects who participated in any other clini-
cal trial during last 30 days and simultaneous participation in
another clinical trial; and (10) Subjects with any condition
which in the opinion of the investigator makes the subject
unsuitable for inclusion.
2.2. Screening and familiarization (Visit 1)
Potential participants (subjects) that were believed to meet
eligibility criteria during Visit 1 (screening visit) were then
invited to attend an entry/familiarization session. During this
session, they signed informed-consent statements and com-
pleted personal and medical histories. Subjects meeting entry
criteria were familiarized with the study protocol via a verbal
and written explanation outlining the study design. This
included describing the training program, familiarizing subjects
with the tests to be performed. Then the baseline assessments
such as medical history, demography physical examination,
laboratory investigations, clinical examination were performed
and recorded in case report forms (CRFs) for the subjects who
consented for the study.
Then subjects reported to the human performance laboratory
for baseline assessments for height (cm), body weight (kg),
heart rate (bpm), respiratory rate (per min), body temperature
(°F), systolic blood pressure (mmHg), and diastolic blood pres-
sure (mmHg). Body mass index (BMI) was calculated as per
formula:Weight (kg)/Height2 (m). The lean body mass (kg) was
calculated as per James’s formula for male22 as: 1.10 × Weight
(kg) − 128 × Weight2 (kg)/100 × Height2 (m).
Demographic and clinical characteristics of all recruited
subjects, intent-to-treat population, are listed by group in Table
1. At baseline, subjects were found uniform with no statistical
significance between the treatment groups with respect to
demographic (age, weight, height) and physiological character-
istics (heart rate, respiratory rate, body temperature, BMI).
Fifty-five out of the 60 recruited subjects (Fenu-FG = 29,
Placebo = 26) consumed at least 1 dose of treatment were
considered as “per protocol”, or “PP population”. Five
subjects (Fenu-FG = 1, Placebo = 4) were dropped out of
study for reasons not related to treatment (such as inconve-
nience or moved out of the area or not adhering to the training
protocol).
2.3. Randomization and baseline assessments visit (Visit 2)
Sixty eligible subjects were randomized to receive 1 of the
2 treatments, namely Fenu-FG (1 capsule, 300 mg, twice a day)
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or matching placebo in 1:1 ratio according to a computer-
generated randomization list. Drop-outs were not replaced.
Subjects were recruited at sites in city of Pune, India. Subjects
were allocated a unique randomization number at randomiza-
tion visit.
After the familiarization/practice session and having base-
line assessments, recruited subjects were instructed to refrain
from exercise for 48 h and fast for 12 h before randomization
and baseline assessment visit (Visit 2) during which the base-
line assessments for efficacy and safety outcome measure were
done and recorded.
2.4. Outcome measures (Visit 2 and Visit 3)
The efficacy outcome measures of study were serum creati-
nine, blood urea nitrogen (BUN), skinfold thickness, % body
fat, androgenic hormone profile (total and free testosterone
levels in blood), muscular strength and repetitions to failure in
bench press and leg press at baseline and end of 8 weeks of
resistance training program.
The skinfold thickness measurement of subcutaneous
tissue of abdominals (thigh), triceps, and chest were with the
help of Lange skinfold caliper (Beta Technology, Santa Cruz,
CA, USA) by well-trained site personal as per manufacture’s
instruction and body fat% was calculated. SKYNDEX
speed rule which is part of the Lange’s skinfold caliper, uses
Jackson–Pollock formula to calculate body fat% from skinfold
thickness measurement.23
2.5. The resistance training and measurements (Visit 2 and
Visit 3)
The protocol outlined by the National Strength and Condi-
tioning Association24 and as described earlier25 was used for
resistance training and muscle strength measurement (1 repeti-
tion maximum (1RM) bench press and 1RM leg press).
Briefly, each subject performed 1RM lifts on the isotonic bench
press. Initially, the subjects were warmed up (2 sets of 8–10
repetitions at approximately 50% of anticipated maximum)
on the bench press and then performed successive 1RM lifts
starting at about 70% of anticipated 1RM and increased
by 5 kg until they reached 1RM. The subjects were again
allowed to rest and warm up by performing 2 sets of the bench
press at 60% and 80% of the resistance. Then, the subject
complete as many repetitions as possible with a resistance of
80% of their 1RM bench press. The subject rested for 10 min
and then warmed up on the 45° leg press (2 sets of 8–10
repetitions at approximately 50% of anticipated maximum).
The same procedure as that of 1RM bench press was adopted
for 1RM leg press. The repetitions to failure in bench
press and leg press was recorded from the number of maximum
repetitions that the subject could complete with a resistance
of 80% of their 1RM bench/leg press. All strength/exercise
tests were supervised by lab assistants experienced in
conducting strength/anaerobic exercise tests using standard
procedures.
2.6. The safety outcome measurements
The safety outcome measures were vital signs (systolic and
diastolic blood pressure, heart rate, respiratory rate, and body
temperature) and the laboratory assessments namely hematol-
ogy, biochemistry (serum creatinine, BUN), and hormonal
profile (serum total testosterone and free testosterone) were
performed on blood samples. Blood hematology parameters
included hematological parameters such as red blood cells
(RBC) count, hemoglobin, hematocrit (HCT), mean corpuscu-
lar volume (MCV), mean corpuscular hemoglobin concentra-
tion (MCHC), total white blood cell (WBC) count, and platelet
count. Biochemical parameters such as random glucose,
alkaline phosphatase (ALP), alanine transaminase (ALT),
aspartate aminotransferase (AST), and bilirubin (total, direct,
and indirect).
2.7. Supplementation/treatment protocol
The study medication (Fenu-FG capsules) was dispensed at
randomization visit and baseline values of outcome measures
were also recorded. Both Fenu-FG and the placebo product
were enclosed in bottles containing capsules that were identical
in function and appearance and individually coded. The active
treatment product is capsules containing 300 mg of Fenu-FG
supplied by manufacturer (Indus Biotech Private Ltd., Pune,
India). The preparation and characterization of Fenu-FG
(HPLC fingerprinting) is reported in earlier research papers.20
Fenu-FG is also active component of marketed formulation,
Testofen. The subjects were instructed to consume 1 capsule
with water twice a day (20 min before breakfast and 20 min
before dinner). The matching capsules containing di-calcium
phosphate (IP grade) was used as placebo treatment. Both
Fenu-FG and placebo were analyzed and complied with quality
requirements related to microbial content or heavy metals. The
treatment period was 8 weeks and subjects visited the study
centers for screening, randomization (baseline), and end of
treatment evaluations. Subjects were monitored for compliance
with the protocol by a telephone or face-to-face communica-
tions from Visit 2 to the end of the 8-week treatment period
(Visit 3).
Table 1
Demographic and baseline characteristics of subjects (mean ± SD).
Characteristics Fenu-FG (n = 30) Placebo (n = 30)
Age (year) 23.21 ± 3.73 21.62 ± 3.96
Height (cm) 165.52 ± 7.02 168.35 ± 6.57
Weight (kg) 65.13 ± 8.51 63.21 ± 9.14
Heart rate (bpm) 76.20 ± 1.69 75.63 ± 2.16
Respiratory rate (per min) 17.17 ± 0.79 17.31 ± 0.71
Body temperature (°F) 97.93 ± 0.25 97.77 ± 0.50
Systolic blood pressure (mmHg) 113.10 ± 7.92 115.00 ± 6.93
Diastolic blood pressure (mmHg) 73.10 ± 7.92 75.23 ± 6.64
Body mass index (kg/m2) 23.73 ± 2.32 22.36 ± 3.39
Lean body mass (kg) 51.68 ± 5.36 51.11 ± 5.35
Note: Intent-to-treat (ITT) population, data were analyzed by unpaired t test for
each parameter.
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2.8. Statistical analysis
The data of efficacy and safety outcome measures were
analyzed using paired t test (within the treatment comparisons)
or unpaired t test (between the groups comparisons) using SPSS
forWindowsVersion 13.0 (SPSS Inc., Chicago, IL, USA). Date
were considered significant when the p < 0.05.
3. Results
The data obtained from muscle strength and repetitions to
failure measurements, serum total and free testosterone levels,
anabolic activity related markers, skinfold thickness measure-
ment and body fat calculations, and safety outcomes such as
blood biochemical and hematological measurements are pre-
sented in Table 2.
3.1. Effect of Fenu-FG on muscle strength and repetitions to
failure
At baseline, no statistical significant difference for 1RM-
bench press, 1RM-leg press, repetitions to failure in bench
press or leg press was found between the group (Fenu-FG vs.
placebo). Similarly, no statistically significant difference was
found in 1RM-bench press responses within the group (at the
end of the study vs. baseline) or between the groups (Fenu-FG
vs. placebo) at the end of the study. However, statistically sig-
nificant increase in 1RM-leg press responses within the
Fenu-FG (73.41 kg vs. 80.45 kg, p < 0.001) and placebo
(74.73 kg vs. 86.85 kg, p < 0.001) group. The increase found in
1RM-leg press responses between the groups (Fenu-FG vs.
placebo) was not statistically significant.
Statistically significant increase was found in repetitions to
failure in bench press for Fenu-FG (7.21 vs. 8.79, p < 0.001)
Table 2
Effect of treatments on muscle strength, repetitions to fail, hormonal parameters; anabolic activity related markers and body fat parameters; safety parameters (serum
biochemistry); safety parameters (hematology) (mean ± SD).
Variable Fenu-FG (n = 29) Placebo (n = 26)
Baseline End Baseline End
Muscle strength and endurance
1RM-bench press (kg) 87.03 ± 29.48 88.24 ± 27.45 76.65 ± 22.57 82.77 ± 29.40
1RM-leg press (kg) 73.41 ± 18.90 80.45 ± 21.15*** 74.73 ± 23.79 86.85 ± 26.03***
Repetitions to failure in bench press (n) 7.21 ± 2.68 8.79 ± 2.26*** 7.12 ± 2.82 6.19 ± 1.59
Repetitions to failure in leg press (n) 8.79 ± 2.11 9.31 ± 2.32 10.04 ± 3.39 9.08 ± 2.51
Serum testosterone measurements
Free testosterone (ng/dL) 17.76 ± 10.98 35.29 ± 15.01*** 21.30 ± 12.24 31.70 ± 19.48**
Total testosterone (ng/dL) 404.95 ± 83.57 452.60 ± 107.87 387.52 ± 86.19 421.27 ± 93.36
Anabolic activity related markers
Serum creatinine (mg/dL) 1.14 ± 0.17 0.94 ± 0.12*** 1.06 ± 0.21 0.97 ± 0.13
BUN (mg/dL) 28.28 ± 4.69 25.62 ± 3.50*** 26.62 ± 4.31 26.42 ± 4.24
Body fat parameters
Skinfold thickness-tricep (mm) 7.48 ± 3.09 5.97 ± 2.33** 7.85 ± 2.44 7.20 ± 3.22
Skinfold thickness-thigh (mm) 9.83 ± 3.37 8.39 ± 3.47* 10.62 ± 3.15 9.57 ± 3.11
Skinfold thickness-chest (mm) 4.86 ± 2.58 3.33 ± 1.98** 5.08 ± 2.26 3.21 ± 1.48***
body fat% 6.30 ± 2.56 4.63 ± 2.49** 6.43 ± 2.34 5.15 ± 2.37
Safety parameters (serum biochemistry)
Glucose-random (mg/dL) 87.66 ± 11.92 86.86 ± 8.66 90.27 ± 12.00 88.92 ± 7.04
AST (IU/L) 25.00 ± 9.47 23.72 ± 5.25 23.96 ± 5.16 23.00 ± 3.39
ALT (IU/L) 32.93 ± 13.61 30.83 ± 10.08 30.04 ± 8.86 28.12 ± 3.88
ALP (IU/L) 75.72 ± 18.06 78.45 ± 14.45 75.31 ± 12.56 80.73 ± 14.09*
Bilirubin (mg/dL)
Total 0.95 ± 0.38 0.91 ± 0.37 0.90 ± 0.23 0.88 ± 0.12
Direct 0.40 ± 0.31 0.36 ± 0.30 0.38 ± 0.18 0.33 ± 0.11
Indirect 0.56 ± 0.10 0.55 ± 0.09 0.53 ± 0.09 0.56 ± 0.06
Safety parameters (hematology)
RBC count (million/mm3) 4.48 ± 0.23 4.49 ± 0.21 4.51 ± 0.44 4.53 ± 0.42
Hemoglobin (%) 13.36 ± 0.72 13.51 ± 0.66 13.46 ± 1.30 13.67 ± 1.24
HCT (%) 40.52 ± 2.13 40.79 ± 2.01 40.58 ± 3.70 41.19 ± 4.01
MCV (femtoliters/cell) 90.50 ± 2.60 88.70 ± 11.26 90.10 ± 2.15 90.97 ± 2.32
MCHC (g/dL) 32.97 ± 0.64 33.12 ± 0.55 33.16 ± 0.54 33.22 ± 0.78
Total WBC (mm3) 9706.90 ± 1225.02 8562.07 ± 1301.49** 8903.85 ± 977.13 8376.92 ± 1449.77
Platelet count (per μL) 257,586.21 ± 55,085.98 260,068.97 ± 45,566.22 255,461.54 ± 4666.74 259,846.15 ± 47,848.67
Note: Per protocol (PP) population, data were analyzed by paired t test for each parameter.
*p < 0.05, **p < 0.01, ***p < 0.001, compared to baseline values of corresponding treatment.
Abbreviations: RBC = read blood cells; 1RM = 1 repetition maximum; BUN = blood urea nitrogen; ALT = alanine transaminase; AST = aspartate aminotransferase;
ALP = alkaline phosphatase; HCT = hematocrit; MCV = mean corpuscular volume; MCHC = mean corpuscular hemoglobin concentration;WBC = white blood cell.
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while placebo group did not show such increase. The Fenu-FG
treated group showed increase in repetitions to failure in bench
press (by 1.59 ± 1.11) whereas placebo group showed decrease
(by 0.92 ± 3.39). This difference (Fenu-FG = +1.59 vs.
placebo = −0.92) between the groups was statistically signifi-
cant (p < 0.001). In case of repetitions to failure in leg press, no
statistically significant difference was found within the groups
(end of the study vs. baseline) or between the groups (Fenu-FG
vs. placebo).
3.2. Effect of Fenu-FG on serum testosterone levels
On 8 weeks of treatment, the levels of free testosterone
was found to have steep (98.7%) increase from baseline (17.76
to 35.29 ng/dL, p < 0.001) in Fenu-FG group whereas placebo
group showed moderate (48.8%) increase from 21.30 to
31.70 ng/dL (p < 0.01). The increase in free testosterone
from baseline (Fenu-FG: 17.53 ± 8.55 ng/dL; placebo:
10.39 ± 14.71 ng/dL) was found significantly between the
groups (p < 0.05).
On 8 weeks of treatment, subjects from Fenu-FG and
placebo groups showed mild but non-significant increased
levels of total testosterone as compared with corresponding
baseline values. The increase in total testosterone from baseline
was also not significant between the treatment groups (Fenu-FG
vs. placebo).
3.3. Effect of Fenu-FG on indirect markers of anabolic
activity
Serum creatinine levels of subjects from Fenu-FG group
showed significant (p < 0.001) reduction whereas serum creati-
nine values of placebo group showed non-significant reduction
(within the groups). The decrease in serum creatinine between
the groups, Fenu-FG (0.20 ± 0.10) and placebo (0.09 ± 0.23),
was found significantly at p < 0.05.
The Fenu-FG treatment showed significant (p < 0.001)
reduction within the group in BUN levels as compared with
baseline values (25.62 vs. 28.28 mg/dL) whereas BUN level
within the placebo group were not statistically significant. BUN
level changes were not found statistically significant between
the groups (Fenu-FG vs. placebo).
3.4. Effect of Fenu-FG on body fat
At the end of the study, subjects with Fenu-FG treatment
showed significant decrease in thigh (p < 0.05), tricep
(p < 0.01), and chest (p < 0.01) as compared with baseline
values. Subjects in placebo group did not show such difference
either in thigh or tricep skinfold thickness measurement.
However, skinfold thickness of chest decreases significantly
(p < 0.001) in placebo group during the study period.
Percent body fat in subjects with Fenu-FG treatment showed
significant (p < 0.01) reduction but not in placebo group.
The decrease in skinfold thickness values or body fat
between the groups (Fenu-FG vs. placebo) was not statistically
significant.
3.5. Effect of Fenu-FG on safety parameters
No significant difference was found within the Fenu-FG and
placebo group when compared with baseline values of bio-
chemical parameters such as random glucose, AST, ALT, bili-
rubin (total, direct, and indirect) and hematological parameters
such as RBC, hemoglobin, HCT, MCV, MCHC, and platelet
count. However, values of ALP showed mild significant
increase in subjects with placebo group (p < 0.05) whereas total
WBC count decreased significantly in Fenu-FG group
(p < 0.01). All values of biochemical and hematological param-
eters were within normal physiological range.
4. Discussion
Fenugreek is commonly used food ingredient in many parts
of the world. Fenugreek glycosides including saponins, sapo-
genins (e.g., diosgenin), similagenin, savsalpogenin, and
yuccagenin26,27 are reported to be major components behind
health benefits of fenugreek seeds.28 The present study
attempted as proof of concept evidence-based pilot study
towards evaluation of traditionally reported androgenic and
anabolic benefits of fenugreek glycosides supplementation on
male subjects during resistance training program. The results of
present clinical study demonstrated the efficacy of 8-week treat-
ment of Fenu-FG offered beneficial effects in terms of repeti-
tions to failure in leg press, free testosterone levels and serum
creatinine as compared with placebo.
Testosterone, a male sex hormone (androgen) is one of the
major hormones involved in anabolic effects (muscle mass,
strength increase). Like most hormones, testosterone is sup-
plied to target tissues in the blood where much of it is trans-
ported bound to a specific plasma protein, sex hormone binding
globulin (SHBG). Testosterone can be measured as “free” (that
is, bioavailable and unbound) or more commonly, “total”
(including the percentage, which is chemically bound to SHBG
and unavailable). The free and nonspecifically bound plasma
hormone levels generally reflect the clinical situation more
accurately than total plasma hormone levels.29 Two major
enzymes involved in testosterone metabolism are
5α-dihydrotestosterone30 and aromatase (CYP19A1).31 In the
present study, Fenu-FG supplementation was found to increase
levels of free testosterone without reduction in total testoster-
one. Our results are in agreement with the recent study where
fenugreek seeds extract supplementation showed increase in
serum testosterone levels in college aged men and perhaps
acted as inhibitor of aromatase and 5α reductase13 and
increased free (i.e., bioavailable and unbound) testosterone by
decreasing the metabolism of serum testosterone. It is impor-
tant to note that the levels of total testosterone were unchanged
between treatment and placebo and well within the physiologi-
cal limits during the present study.
The relationship between serum testosterone levels and
libido is well established.32 The recent double-blind randomized
placebo-control study demonstrated beneficial effects of fenu-
greek seeds extract powder enhancing male libido in healthy
adult males.33 In the present study, Fenu-FG supplementation
was found to increase free serum testosterone levels as com-
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pared with placebo group. Testosterone plays a key role in the
development of bone mass, increased bone density and
strength, stimulation of linear growth and bone maturation.
Increased levels of free testosterone was found to be correlated
well with indirect measures of anabolic activity of Fenu-FG
supplementation observed during the study.
Muscle endurance refers to the ability of a muscle to
perform a continuous effort without fatiguing (repetitions to
failure). Cycling, step machines, and sit-up tests are often used
to measure muscular endurance. A fenugreek seeds extract is
reported to enhance swimming endurance capacity in mice
in vivo perhaps by utilization of fatty acids as an energy source
and spares glycogen.12 In our study, increased number of rep-
etitions to failure during resistance training was observed in
subjects with Fenu-FG supplemented subjects whereas placebo
supplemented subjects showed decrease. In addition, significant
decrease in serum creatinine and BUN levels in Fenu-FG
treated subjects is probable indicator of anabolic activity.
In the present study, significant reduction in body fat and
skinfold thickness (thigh and tricep) was observed by 8 weeks
of treatment of Fenu-FG with non-significant increase in
muscle strength and significant increase in repetitions to failure.
These physiological effects can be attributed to marker com-
pounds, furostanol glycosides that are present in Fenu-FG
supplementation. In the past, furostanol glycosides fraction of
Trigonella foenum-graecum showed potent anabolic and fat
burning activity in immature castrated male rats.20 Further, role
for furostenol glycoside from Trigonella foenum-graecum seeds
especially diosgenin in hormone mediated activity pathways
has also been reported.34,35
Diosgenin has various effects on cholesterol metabolism,
one of the most important being the capacity to lower plasma
cholesterol concentration in hypercholestemic animals.36 The
hypocholesterolaemic effect of diosgenin has been suggested to
depend on its capacity to inhibit cholesterol absorption,
increase biliary cholesterol secretion, increase faecal excretion
of neutral sterols and thus to decrease liver cholesterol
concentrations.37 Further, fenugreek saponins are shown, at
least partly, responsible for antihyperlipidemic effects in over-
weight men with erectile dysfunction38 mediated through inhi-
bition of fat accumulation and up-regulation of Low-density
lipoprotein receptor.39
The results of earlier studies on fenugreek seeds extract40
indicate that saponins present in fenugreek do not interact
directly with cholesterol but have a strong inhibitory effect on
bile salt absorption40 in a quantitative manner. Other reports41,42
of increased faecal weight and excretion of bile acids by fenu-
greek enriched diets support the notion. The blood and hepatic
cholesterol lowering may be due to a subsequent increase in the
conversion of cholesterol to bile acids by the liver. Taken
together, observed benefits of Fenu-FG in the present study may
lead to improved lipid profile through bile salt mechanism in
exercising subjects as indicated by body fat improvement
observed in the present study.
The resistance exercise is known for the beneficial effects on
strength, endurance, and serum testosterone levels. The signifi-
cance between the groups is only possible in case of excellent
effect over and above the beneficial levels offered by exercise.
In the present study, statistical significance was achieved
between the groups for some of the outcome measures (serum
free testosterone, serum creatinine, and repetitions to failure
during leg press). In case of other outcome measures, Fenu-FG
supplementation showed superior effects as compared with
placebo without statistical significance between the groups
(BUN, skinfold thickness, and body fat%). In these cases,
extent of effects was perhaps not sufficient for statistical sig-
nificance between the groups. Probably longer duration of study
in more subjects could have shown statistical significance.
Therefore, the present pilot study is indicative of beneficial
effects of Fenu-FG supplementation to the resistance exercise.
Fenugreek is certified as GRAS ingredient in USA and so
the risk of inherent toxicity is very low. The results of present
study supported the safety of Fenu-FG on chronic administra-
tion. The level of blood biochemical and hematological param-
eters in Fenu-FG treated subjects were found within normal
physiological range throughout the study period. No serious
adverse event occurred during the study period. The treatment
was found to be safe and well tolerated.
5. Conclusion
In conclusion, Fenu-FG supplementation showed promising
anabolic and androgenic effects in male subjects during 8
weeks of resistance training program in a double-blind random-
ized placebo-controlled study without serious adverse events.
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